Stocks Health care NERV
NASDAQ · Health careMinerva Neurosciences, Inc. (NERV)
It posted a net loss of $290.9M. At September 30, 2026 it held $20.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Minerva Neurosciences, Inc.
- Net worth
- Minerva Neurosciences, Inc. has a market value (market cap) of $125.6M at the latest share price, and shareholders' equity of -$97.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $13.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Minerva Neurosciences, Inc.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Minerva Neurosciences, Inc. does
Minerva Neurosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NERV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$293.4M | -$34.67 | n/a |
| 2024 | $0 | $1.4M | $0.19 | n/a |
| 2023 | $0 | -$30M | -$4.61 | n/a |
| 2022 | $0 | -$32.1M | -$6.01 | -$24.7M |
| 2021 | $0 | -$49.9M | -$9.35 | n/a |
| 2020 | $41.2M | $1.9M | $0.40 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Minerva Neurosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- November 6, 2026
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 7, 2026
- August 7, 2026
- June 4, 2026
- May 27, 2026
Insider trades
What the people running Minerva Neurosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns NERV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 9.99% | August 14, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 9.99% | February 20, 2026 |
| Dapice Joshua J.13G, passive with 28 related filers | 9.99% | February 5, 2026 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 9.99% | December 31, 2025 |
| Janus Henderson Group PLC13G, passive | 9.9% | May 15, 2026 |
| Logos Global Management LP13G, passive with 5 related filers | 9.9% | February 17, 2026 |
| Farallon Capital Management, L.L.C.13G, passive with 26 related filers | 9.7% | August 13, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 6.35% | February 12, 2026 |
| BlackRock, Inc.13G, passive | 5.1% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 58 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Federated Hermes, Inc. | 4,670,426 | -442,798 |
| Jupiter Topco LLC | 4,386,027 | new |
| Vivo Capital, LLC | 4,322,747 | 0 |
| Balyasny Asset Management L.P. | 4,257,000 | -1,600 |
| Logos Global Management LP | 3,288,777 | +73,777 |
| Farallon Capital Management, L.L.C. | 2,365,000 | 0 |
| BlackRock, Inc. | 2,240,578 | +1,615,721 |
| Ally Bridge Group (NY) LLC | 2,175,802 | +520,302 |
| Foresite Capital Management VI LLC | 1,985,584 | -1,016 |
| Vanguard Capital Management LLC | 1,892,807 | +46,976 |
| Spruce Street Capital LP | 1,655,500 | 0 |
| Adage Capital Partners GP, L.L.C. | 1,419,000 | 0 |
| Trails Edge Capital Partners, LP | 1,419,000 | 0 |
| Seven Fleet Capital Management LP | 1,001,373 | +752,897 |
| Geode Capital Management, LLC | 974,236 | +635,501 |
| DV Equities, LLC | 754,397 | new |
| Acuta Capital Partners, LLC | 709,500 | 0 |
| Millennium Management LLC | 533,602 | -174,689 |
| State Street Corp | 424,915 | +368,566 |
| Vanguard Fiduciary Trust Co | 302,604 | +38,557 |
Insiders
Questions about NERV
What does Minerva Neurosciences, Inc. do?
Minerva Neurosciences, Inc. is a company in the Health care sector, listed on NASDAQ as NERV. Its shares trade on NASDAQ under the ticker NERV.
What is Minerva Neurosciences, Inc.'s net worth?
Minerva Neurosciences, Inc. has a market value (market cap) of $125.6M at the latest share price, and shareholders' equity of -$97.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Minerva Neurosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $290.9M.
When did Minerva Neurosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Minerva Neurosciences, Inc.'s next earnings report?
Minerva Neurosciences, Inc.'s next report is expected around February 5, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NERV with
Follow NERV
Get an email when Minerva Neurosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Minerva Neurosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.